Loading
A phase 3 trial of Cisplatin, Cyclophosphamide, Lomustine, Sodium thiosulfate and Vincristine in Medulloblastoma, run by Children's Oncology Group, now recruiting.
A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss is a phase 3 interventional study registered as NCT05382338 by Children's Oncology Group, with 225 participants planned, started 2023-02-20 and due to reach its primary completion in 2029-12-31. Interventions recorded: Audiometric Test, Auditory Brainstem Response, Biospecimen Collection, Cisplatin, Cyclophosphamide, Lomustine, Magnetic Resonance Imaging, Quality-of-Life Assessment, Radiation Therapy, Sodium Thiosulfate, Survey Administration, Vincristine. Conditions recorded: Childhood Medulloblastoma.
Linked to the drug Sodium thiosulfate because the registry names it among its interventions and Medulloblastoma among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Sodium thiosulfate (otoprotectant), Cisplatin and the tag pipeline.
Shares Sodium thiosulfate (otoprotectant), Children's Oncology Group (COG) and the tag pipeline.
Shares Lomustine (CCNU) and the tag pipeline.
Shares Children's Oncology Group (COG), Vincristine, Cyclophosphamide and the tag pipeline.
Shares Vincristine, Cyclophosphamide and the tag pipeline.
Shares Vincristine, Cyclophosphamide and the tag pipeline.
Shares Children's Oncology Group (COG), Vincristine, Cyclophosphamide and the tag pipeline.
Shares Vincristine, Cyclophosphamide and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/